AGP Executive Report
Last update: 8 hours agoDigital Care: Oura agreed to buy Counsel Health for $625 million, aiming to connect wearable data with AI-supported clinical care. Vaccine Development: AstraZeneca acquired Omniose, adding a bioconjugation platform for developing vaccines against serious bacterial infections. Drug Safety: The FDA is requiring GLP-1 medicines to warn of a rare risk of vision loss. Stroke Prevention: The FDA approved Bayer’s Sunharbo (asundexian) to reduce the risk of another stroke. Rare Disease Treatment: Merck’s Pimjetmi won US approval for adults with symptomatic tenosynovial giant cell tumors when surgery could cause serious harm; the trial showed a 56% tumor response rate. Maternal Mental Health: Lipocine began a Phase III trial of an at-home oral treatment for postpartum depression. Medical Manufacturing: India extended its medical-device production incentive scheme through 2035–36 and invited new applications.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/30265330-956093879-441380d25ae461dade2f2b38b529c638e3dfb8f2-1890x1063-200x113.png)
